

LIST OF CONTRIBUTORS

- Pedro Pita Barros* Faculdade de Economia,
Universidade Nova de Lisboa (UNL),
Lisbon, Portugal
- Didem Bernard* Center for Finance, Access, and Cost
Trends, Agency for Healthcare Research
and Quality, Rockville, MD, USA
- Lieke H. H. M. Boonen* Institute of Health Policy and
Management (iBMG), Erasmus University
Rotterdam, Rotterdam, The Netherlands
- John F. P. Bridges* Johns Hopkins University, Baltimore,
MD, USA
- John M. Brooks* College of Pharmacy, The University of
Iowa, Iowa City, IA, USA
- Jane Castelli-Haley* Teva Neuroscience Inc, Kansas City,
MO, USA
- Jie Chen* College of Staten Island, City University
of New York, New York, NY, USA
- Shin-Yi Chou* Department of Economics, Lehigh
University, Bethlehem, PA, USA
- Joshua P. Cohen* Tufts Centre for the Study of Drug
Development, Boston, MA, USA
- Mary E. Deily* Department of Economics, Lehigh
University, Bethlehem, PA, USA
- Avi Dor* George Washington University,
Washington, DC, USA, and NBER,
New York, NY, USA
- William R. Doucette* College of Pharmacy, The University
of Iowa, Iowa City, IA, USA

<i>William E. Encinosa</i>	Center for Delivery, Organization, and Markets, Rockville, MD, USA, and Georgetown University, Washington, DC, USA
<i>Adam Gailey</i>	RAND Corporation, Santa Monica, CA, USA
<i>Stéphanie A. van der Geest</i>	Institute of Health Policy and Management (iBMG), Erasmus University Rotterdam, Rotterdam, The Netherlands
<i>Teresa Bernard Gibson</i>	Thomson-Reuters, Ann Arbor, MI, USA
<i>Peter G. Grist</i>	John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
<i>Jack Hoadley</i>	Health Policy Institute, Georgetown University, Washington, DC, USA
<i>Maureen J. Lage</i>	Health Metrics Outcomes Research, Groton, CT, USA
<i>Darius Lakdawalla</i>	University of Southern California, Los Angeles, CA, USA, and RAND Corporation, Santa Monica, CA, USA
<i>Frank R. Lichtenberg</i>	Graduate School of Business, Columbia University, New York, NY, USA
<i>Hsien-Ming Lien</i>	Department of Public Finance, National Cheng-Chi University, Taipei, Taiwan
<i>Catherine G. McLaughlin</i>	School of Public Health, University of Michigan, Ann Arbor, MI, USA
<i>Axel C. Mühlbacher</i>	Hochschule Neubrandenburg, Neubrandenburg, Germany
<i>Yuriy Pylypchuk</i>	Social and Scientific Systems, Agency for Healthcare Research and Quality, Rockville, MD, USA

- John A. Rizzo* Department of Economics and
Department of Preventive Medicine,
Stony Brook University, Stony Brook,
NY, USA
- Philip Sax* Centre for Drug Studies, PHARMA
Drug Bulletin, Jerusalem, Israel
- Frederik T. Schut* Institute of Health Policy and
Management (iBMG), Erasmus University
Rotterdam, Rotterdam,
The Netherlands
- Amir Shmueli* Hebrew University, Jerusalem, Israel
- Kosali Simon* Department of Policy Analysis and
Management, Cornell University,
Ithaca, NY, USA
- Dean G. Smith* School of Public Health, University of
Michigan, Ann Arbor, MI, USA
- Neeraj Sood* University of Southern California,
Los Angeles, CA, USA, and RAND
Corporation, Santa Monica, CA, USA
- Marcy L. Tarrant* Teva Neuroscience Inc, Kansas City,
MO, USA
- Julie M. Urmie* College of Pharmacy, The University
of Iowa, Iowa City, IA, USA
- Marco Varkevisser* Institute of Health Policy and
Management (iBMG), Erasmus University
Rotterdam, Rotterdam, The Netherlands
- Yang Xie* College of Pharmacy, The University
of Iowa, Iowa City, IA, USA
- Jing Hua Zhang* Department of Economics, Lehigh
University, Bethlehem, PA, USA